Management of poisoning by amphetamine or ecstasy

Author(s):  
Enno Freye

While amphetamine and especially methamphetamine (speed) is being misused by all social classes in order to increase stamina, intellectual expansion, endurance, and euphoria, the drug 3,4-methylenedioxy-N-methylamphetamine (MDMA) (ecstasy) is preferentially abused by the younger generation for the feeling of empathy, the touching within, and enhancement of the senses. Acute intoxication differs in regard to their effects on the person. The predominant sympathetic overstimulation after methamphetamine results in cardiovascular and CNS hyperactivity accompanied by agitation and seizures, while tachycardia is a prodrome of fibrillation. The excess hypertonia often leads into myocardial infarction and may even induce cerebral haemorrhage. MDMA intoxication often seen in the emergency department is predominantly characterized by hyperthermia, the most important condition to treat, followed by rhabdomyolysis and acute renal failure. Since there is no specific antidote available, in both cases therapy consists of treatment until the acute effects are gone.

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Osman Zikrullah Sahin ◽  
Teslime Ayaz ◽  
Suleyman Yuce ◽  
Fatih Sumer ◽  
Serap Baydur Sahin

Introduction. Acute renal failure (ARF) develops in 33% of the patients with rhabdomyolysis. The main etiologic factors are alcoholism, trauma, exercise overexertion, and drugs. In this report we present a rare case of ARF secondary to probably donepezil-induced rhabdomyolysis.Case Presentation. An 84-year-old male patient was admitted to the emergency department with a complaint of generalized weakness and reduced consciousness for two days. He had a history of Alzheimer’s disease for one year and he had taken donepezil 5 mg daily for two months. The patient’s physical examination revealed apathy, loss of cooperation, and decreased muscle strength. Laboratory studies revealed the following: urea: 128 mg/dL; Creatinine 6.06 mg/dL; creatine kinase: 3613 mg/dL. Donepezil was discontinued and the patient’s renal function tests improved gradually.Conclusion. Rhabdomyolysis-induced acute renal failure may develop secondary to donepezil therapy.


2005 ◽  
Vol 62 (3) ◽  
pp. 235-241 ◽  
Author(s):  
Radoje Ilic ◽  
Zoran Trifunovic ◽  
Svetislav Tisma ◽  
Andjelka Ristic-Andjelkov ◽  
Milic Veljovic

Aim. The case of successful surgical treatment of anterolateral papillary muscle rupture due to acute myocardial infarction with cardiogenic shock, pulmonary edema and acute renal failure. Case report. A 62-year old male from Belgrade with chest pain, hypotension and a new heart murmur refused hospitalization at the Military Medical Academy. On the third day of his illness he was readmitted to MMA as an emergency due to hemoptysis. Examination revealed mitral valve anterolateral papillary muscle rupture. The patient, with signs of cardiogenic shock and acute renal failure, was immediately operated on. The surgery was performed using extracorporeal circulation. An artificial mitral valve was implanted, and myocardial revascularization accomplished with one venous graft of the left anterior descending artery. On the second postoperative day, hemodialysis was carried out due to acute renal failure. On the 28th postoperative day, the patient was discharged from the hospital being hemodynamically stable with normal renal function and balanced anticoagulation. The case is interesting in terms of unrecognized papillary muscle rupture that led to the development of cardiogenic shock, hemoptysis and acute renal failure. Conclusion. Papillary muscle rupture is a fatal complication of acute myocardial infarction. Early recognition and urgent surgical intervention were lifesaving in the case of complete papillary muscle rupture. Surgical treatment, regardless of high risk, is the procedure of choice.


Nephron ◽  
1984 ◽  
Vol 37 (3) ◽  
pp. 213-214 ◽  
Author(s):  
Dino Docci ◽  
Maurizio Mambelli ◽  
Giuseppe Manzoni ◽  
Fausto Turci ◽  
Giovanni Salvi

CJEM ◽  
2010 ◽  
Vol 12 (05) ◽  
pp. 457-459 ◽  
Author(s):  
Brian E. Grunau ◽  
Matthew O. Wiens ◽  
Marc Greidanus

ABSTRACTMDMA (3,4-methylenedioxymethamphetamine), popularly known as “Ecstasy,” was first introduced and patented by Merck & Co., Inc., in 1914 as an appetite suppressant. Currently, its primary role is as an illegal stimulant used to produce a euphoric effect during parties. This case report describes a 31-year-old man who, after taking 3 tablets of Ecstasy, presented to an emergency department with a decreased level of consciousness and became progressively hyperthermic and rigid. During the course of his acute illness, his temperature reached 42.2°C rectally. He was given mechanical ventilation. He was aggressively cooled and dantrolene was initiated. Soon after the administration of dantrolene his temperature decreased and his rigidity began to resolve. The only complication was rhabdomyolysis with a creatine kinase level increasing to over 150 μkat/L. This did not progress to acute renal failure. The patient made a full recovery and was discharged to psychiatry for assessment.


2002 ◽  
Vol 112 (2) ◽  
pp. 115-119 ◽  
Author(s):  
Maria Koreny ◽  
Georg Delle Karth ◽  
Alexander Geppert ◽  
Thomas Neunteufl ◽  
Ute Priglinger ◽  
...  

Drug Safety ◽  
2020 ◽  
Vol 43 (9) ◽  
pp. 927-942
Author(s):  
Rachel B. Weinstein ◽  
Patrick B. Ryan ◽  
Jesse A. Berlin ◽  
Martijn J. Schuemie ◽  
Joel Swerdel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document